Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116389 · ClinicalTrials.gov registry record · Phase 2
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by Point Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00116389 is a Phase 2 study that was terminated before completion, run by Point Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT00116389, a Phase 2 study, was terminated before completion, sponsored by Point Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
Interventions
- DRUG gemcitabine
- DRUG talabostat mesylate tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116389
The ClinicalTrials.gov registry entry for NCT00116389 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00116389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116389 about?
NCT00116389 is a clinical study titled "Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas". The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
What is the current status of trial NCT00116389?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00116389?
The interventions under investigation include: gemcitabine (DRUG), talabostat mesylate tablets (DRUG).
Who is sponsoring clinical trial NCT00116389?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.